Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Apogee Therapeutics Inc (APGE)

Apogee Therapeutics Inc (APGE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Apogee Therapeutics to Participate in Upcoming Conferences GlobeNewswire - Mon Nov 3, 6:30AM CST

SAN FRANCISCO and BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate at the following investor conferences....

APGE : 54.71 (-0.52%)
Apogee Therapeutics Raises $323.3 Million in Offering Tipranks - Sat Oct 11, 5:38AM CDT

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Apogee Therapeutics...

APGE : 54.71 (-0.52%)
Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering GlobeNewswire - Wed Oct 8, 8:52PM CDT

SAN FRANCISCO and BOSTON, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class...

APGE : 54.71 (-0.52%)
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering GlobeNewswire - Wed Oct 8, 3:01PM CDT

SAN FRANCISCO and BOSTON, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class...

APGE : 54.71 (-0.52%)
Canaccord Genuity Sticks to Their Buy Rating for Apogee Therapeutics (APGE) Tipranks - Sat Oct 4, 7:26AM CDT

In a report released today, Edward Nash from Canaccord Genuity maintained a Buy rating on Apogee Therapeutics, with a price target of $89.00. The company’s shares closed yesterday at $39.61.Elevate Your...

APGE : 54.71 (-0.52%)
Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress GlobeNewswire - Thu Sep 11, 6:30AM CDT

SAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for...

APGE : 54.71 (-0.52%)
Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum GlobeNewswire - Wed Sep 3, 6:30AM CDT

SAN FRANCISCO and BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Stifel 2025...

APGE : 54.71 (-0.52%)
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results GlobeNewswire - Mon Aug 11, 6:00AM CDT

Positive 16-week data from APEX Phase 2 Part A met all primary and key secondary endpoints for APG777, a potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis APEX...

APGE : 54.71 (-0.52%)
Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis GlobeNewswire - Mon Jul 7, 5:00AM CDT

APGE : 54.71 (-0.52%)
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025 GlobeNewswire - Sun Jul 6, 5:00PM CDT

APGE : 54.71 (-0.52%)

Barchart Exclusives

Why Is Everyone Watching Palantir Stock? Barchart - Sat Nov 8, 11:00AM CST
After two decades of quiet development, Palantir has found its moment. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot